Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBT Margin (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBT Margin for 10 consecutive years, with 45.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 13307.0% year-over-year to 45.91%, compared with a TTM value of 6.27% through Dec 2025, up 24347.0%, and an annual FY2025 reading of 5.57%, up 15353.0% over the prior year.
  • EBT Margin was 45.91% for Q4 2025 at Anaptysbio, up from 30.23% in the prior quarter.
  • Across five years, EBT Margin topped out at 45.91% in Q4 2025 and bottomed at 3237.84% in Q1 2022.
  • Average EBT Margin over 5 years is 919.62%, with a median of 433.95% recorded in 2022.
  • The sharpest move saw EBT Margin crashed -312314bps in 2021, then skyrocketed 263239bps in 2022.
  • Year by year, EBT Margin stood at 3075.07% in 2021, then skyrocketed by 86bps to 442.68% in 2022, then fell by -6bps to 468.32% in 2023, then skyrocketed by 81bps to 87.16% in 2024, then soared by 153bps to 45.91% in 2025.
  • Business Quant data shows EBT Margin for ANAB at 45.91% in Q4 2025, 30.23% in Q3 2025, and 173.34% in Q2 2025.